Assistant Investigator, Chinese Institutes for Medical Research, Beijing, China

Postdoctoral Research Associate, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, USA

 

Chimeric antigen receptor cell immunotherapy (CAR-T) is a new type of immunotherapy that engineers human immune cells to kill tumors. It has achieved remarkable results in leukemia, lymphoma, and multiple myeloma, and there are currently many commercial products worldwide. However, significant challenges remain in enhancing its efficacy against solid tumors. The Zhou Laboratory at CIMR is dedicated to developing and optimizing next-generation CAR-T cell therapies, with a particular focus on innovative cell engineering strategies to improve their effectiveness in solid tumors.